目的:探究大剂量丙种球蛋白对扩张型心肌病(DCM)心力衰竭患者心肌肌凝蛋白重链(CMHC)自身免疫球蛋白G(IgG)抗体滴度和临床疗效的影响。方法:选择2011年3月~2014年5月我院心内科收治的DCM心力衰竭患者160例。按照随机数字表法,患者被随机均分分为常规治疗组(80例)和丙种球蛋白组(80例,在常规治疗组基础上接受大剂量丙种球蛋白治疗)。观察比较两组患者治疗前后的心功能指标,IgG抗体滴度以及血清心肌肌钙蛋白T(cTnT)和cTnI水平。结果:与治疗前比较,治疗6个月后丙种球蛋白组左室舒张末期内径[LVEDd,(67.50±5.50)mm比(56.50±2.50)mm]和左室收缩末期内径[LVESd,(55.50±6.80)mm比(43.50±2.30)mm]显著降低,左室射血分数[LVEF,(33.50±3.50)%比(53.50±8.50)%]显著升高,而常规治疗组仅LVEF[(32.80±4.20)%比(41.50±5.50)%]显著升高,P均〈0.05;与常规治疗组比较,治疗6个月后丙种球蛋白组的LVEDd[(63.50±2.50)mm比(56.50±2.50)mm]和LVESd[(51.60±4.80)mm比(43.50±2.30)mm]显著降低,LVEF显著升高,P均〈0.05。治疗1、3、5和6个月后,丙种球蛋白组IgG抗体滴度显著降低,且均显著低于同期常规治疗组的(P均〈0.05)。治疗6个月后两组cTnT和cTnI水平均较治疗前显著减低(P均〈0.05),且与常规治疗组比较,丙种球蛋白组cTnT[(0.55±0.10)μg/L比(0.26±0.02)μg/L]和cTnI水平[(1.20±0.40)μg/L比(0.60±0.10)μg/L]下降更显著(P均〈0.05)。结论:大剂量丙种球蛋白治疗扩张型心肌病心力衰竭患者,能够显著改善患者的心肌功能,明显降低心肌肌凝蛋白重链自身IgG抗体水平,显著降低血清肌钙蛋白T和I的含量,值得在临床上推广。
Objective.. To explore influence of large dose , globulin on myocardial cardiac myosin heavy chain (CM- HC) own IgG antibody titer and therapeutic effect in patients with dilated cardiomyopathy (DCM) heart failure (HF). Methods: A total of 160 DCM + HF patients hospitalized in our department of cardiology from Mar 2011 toMay 2014 were selected. According to random number table, they were randomly and equally divided into routine treatment group (n = 80, RT group) and )' globulin group (n = 80, received large dose ) globulin therapy based on RT group). Cardiac function indexes, IgG antibody titer and serum levels of cTnT and cTnI were observed and com- pared between two groups before and after treatment. Results: Compared with before treatment after six- month treatment, there were significant reductions in LVEDd [ (67.50 ± 5.50) mm vs. (56.50 ±2.50) mm] and LVESd [ (55.50±6.80) mm vs. (43.50±2.30) mm], and significant rise in LVEF [ (33.50±3.50)% vs. (53.50±8.50) %] in y globulin group, and only LVEF significantly rose [ (32.80±4. 20) % vs. (41.50±5.50) %] in RT group, P〈0.05 all; compared with RT group after six- month treatment, there were significant reductions in LVEDd [ (63.50 ± 2.50) mm vs. (56.50 ± 2.50) mini and LVESd [ (51.60 ± 4.80) mm vs. (43.50 ± 2.30) mm], and significant rise in LVEF in 7 globulin group, P〈0.05 all. On one, three, five and six months after treatment, IgG antibody titer significantly reduced in 7 globulin group and they were significantly lower than those of RT group (P〈0. 05 all). After six- month treatment, cTnT and cTnI levels of both groups were significantly lower than those of before treatment (P〈0.05 all), compared with RT group, there were significant reductions in cTnT [- (0.55±0.10) μg/L vs. (0.26±0.02) μg/L] and cTnI levels [ (1.20 ± 0.40) μg/L vs. (0.60 ± 0.10) μg/L] in 7 globulin group, P〈0.05 both. Conclusion.. Large dose 7 globulin can s